Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.53 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.53 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.53 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.53 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.53 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.53 |
| ▸ | PSMA4 | P25789 | 1/20 | 0.53 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.53 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.53 |
| ▸ | PSMA5 | P28066 | 1/20 | 0.53 |
| ▸ | PSMB4 | P28070 | 1/20 | 0.53 |
| ▸ | PSMB6 | P28072 | 1/20 | 0.53 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.53 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.53 |
| ▸ | PSMB3 | P49720 | 1/20 | 0.53 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.53 |
| ▸ | PSMA6 | P60900 | 1/20 | 0.53 |
| ▸ | PSMA8 | Q8TAA3 | 1/20 | 0.53 |
| ▸ | PSMB7 | Q99436 | 1/20 | 0.53 |
| ▸ | CES2 | O00748 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13292609 | 0.87 | PSMB5 (0.51) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL15610344 | 0.86 | CES2 (0.53) | CES2CES1EGLN1RAB9A | |
| SCHEMBL5314181 | 0.86 | CES2 (0.57) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL343657 | 0.85 | MEN1 (0.49) | EGLN1RAB9AMAPK8 | |
| SCHEMBL29195069 | 0.85 | EGLN1 (0.46) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL15630978 | 0.83 | KEAP1 (0.59) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL21810711 | 0.83 | F2R (0.47) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL15630980 | 0.83 | RAB9A (0.50) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL21841256 | 0.83 | EGLN1 (0.55) | PSMB11PSMA7PSMB1PSMA1PSMA2 | |
| SCHEMBL21841322 | 0.83 | EGLN1 (0.48) | EGLN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3851108-B1 | BORATE-BASED DRUG AND USE THEREOF | CHENGDU ORIGIN BIOTECHNOLOGY LTD COMPANY (CN) | 2023-08-09 | — | — | EP | disclosed |
| US-20210332069-A1 | Borate-Based Drug And Use Thereof | CHENGDU ORIGIN BIOTECHNOLOGY LIMITED COMPANY (CN) | 2021-10-28 | — | — | US | disclosed |
| EP-3851108-A1 | BORATE-BASED DRUG AND USE THEREOF | Chengdu Origin Biotechnology Limited Company (CN) | 2021-07-21 | — | — | EP | disclosed |
| WO-2020052488-A1 | BORATE-BASED DRUG AND USE THEREOF | 成都奥璟生物科技有限公司 | 2020-03-19 | — | — | WO | disclosed |
| US-8912341-B2 | Enantioselective N-heterocyclic carbene-catalyzed annulation reactions with imidazolidinones | NORTHWESTERN UNIVERSITY (US) | 2014-12-16 | — | — | US | disclosed |
| US-8835422-B2 | Substituted imidazoheterocycle derivatives | CARA THERAPEUTICS, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8835422-B2 | Substituted imidazoheterocycle derivatives | CARA THERAPEUTICS, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20140206886-A1 | Enantioselective N-heterocyclic carbene-catalyzed annulation reactions with imidazolidinones | NORTHWESTERN UNIVERSITY (US) | 2014-07-24 | — | — | US | disclosed |
| US-20120015930-A1 | SUBSTITUTED IMIDAZOHETEROCYCLE DERIVATIVES | CARA THERAPEUTICS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015930-A1 | SUBSTITUTED IMIDAZOHETEROCYCLE DERIVATIVES | CARA THERAPEUTICS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| WO-2010068520-A2 | SUBSTITUTED IMIDAZOHETEROCYCLE DERIVATIVES | CARA THERAPEUTICS, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210332069-A1 | Borate-Based Drug And Use Thereof | PSMB11, PSMB1, PSMB3 | PSMB11 1/4885PSMA7 43/4885PSMB1 2/4885 |
| US-20140206886-A1 | Enantioselective N-heterocyclic carbene-catalyzed annulation reactions with imidazolidinones | NISCH, NIM1K, CDK18 | PSMB11 3944/4885PSMA7 4622/4885PSMB1 4177/4885 |
| US-20120015930-A1 | SUBSTITUTED IMIDAZOHETEROCYCLE DERIVATIVES | CNR1, CNR2, HRH1 | PSMB11 3333/4885PSMA7 2648/4885PSMB1 3976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.